Acacia Pharma Ltd is planning to list its stock on the Euronext Brussels stock exchange.
The privately held U.K. company will use the initial global offering to raise funds for Baremsis, which is meant to treat post-surgery nausea and vomiting.
The medicine is under review in the U.S. and is expected to be launched early next year. The company plans to establish a sales force that will help commercialize the drug.
The company is also developing APD403 to treat nausea and vomiting in cancer patients receiving chemotherapy and will also funnel funds toward that effort.
Bank Degroof Petercam NV/SA and RBC Europe Ltd. are acting as joint global coordinators for the global offering.
